API

Small Molecules

 

Small molecules still form the majority of all compounds used in pharmaceutical products. Often sustained release is used to reduce toxicity of these molecules. Important here is that release of the molecule is sufficiently controlled to avoid toxic levels in the blood stream.

InnoCore has several sustained release technologies that can easily be tailored to manufacture sustained release small molecule injectables. They can be used for local as well as for systemic drug delivery of small molecules for up to 6 months.

The top ten benefits of our sustained release technologies for small molecules:

• Several formulation possibilities, including microspheres, gels, coatings and implants

• Multi-block polymeric architectures that offers endless possibilities for fine tuning of properties

• Release in a controlled manner by diffusion which can be tuned by variation of the SynBiosys® or InGell® building blocks ratio resulting in limited or no burst

• Optimal control over the physico-chemical and degradation characteristics: for our biodegradable polymers, a rule of thumb for 1-month sustained delivery formulation, the polymers will be cleared in not more than two months.

• Protection from high shear forces during processing

• Protection from increased temperature (during processing and storage)

• High loading (e.g. 40-50% for microspheres) and high encapsulation efficiency (e.g. on average higher than 80% for microspheres)

• Protection by the matrix from environmental influences, like proteases

• For gels, easy process and scale up conditions

• InnoCore’s patented technologies has several advantages compared to PLGA polymers with respect to life cycle management

 

Read more about our polymer platform SynBiosys® and InGell®